Trial Profile
A randomized, 12 months, active controlled study of the efficacy of repeated doses of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- 24 Nov 2016 New trial record